Targeting PFKFB3 alleviates cerebral ischemia-reperfusion injury in mice

Olga Burmistrova1, Ana Olias-Arjona2, Rebeca Lapresa2,3, Daniel Jimenez-Blasco2,3,4, Tatiana Eremeeva1, Dmitry Shishov1, Sergei Romanov5, Kristina Zakurdaeva1, Angeles Almeida2,3, Peter O. Fedichev1 & Juan P. Bolaños2,3,4

The glycolytic rate in neurons is low in order to allow glucose to be metabolized through the pentose-phosphate pathway (PPP), which regenerates NADPH to preserve the glutathione redox status and survival. This is controlled by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3), the pro-glycolytic enzyme that forms fructose-2,6-bisphosphate, a powerful allosteric activator of 6-phosphofructo-1-kinase. In neurons, PFKFB3 protein is physiologically inactive due to its proteasomal degradation. However, upon an excitotoxic stimuli, PFKFB3 becomes stabilized to activate glycolysis, thus hampering PPP mediated protection of redox status leading to neurodegeneration. Here, we show that selective inhibition of PFKFB3 activity by the small molecule AZ67 prevents the NADPH oxidation, redox stress and apoptotic cell death caused by the activation of glycolysis triggered upon excitotoxic and oxygen-glucose deprivation/reoxygenation models in mouse primary neurons. Furthermore, in vivo administration of AZ67 to mice significantly alleviated the motor discoordination and brain infarct injury in the middle carotid artery occlusion ischemia/reperfusion model. These results show that pharmacological inhibition of PFKFB3 is a suitable neuroprotective therapeutic strategy in excitotoxic-related disorders such as stroke.

Glycolysis is widely considered a pro-survival metabolic pathway because it meets the energy needs of cells during mitochondrial bioenergetic stress1. However, in the brain tissue, different cell types show distinct metabolic preferences2–4. For instance, the metabolic use of glucose through glycolysis in neurons is normally very low, being mainly metabolized through the pentose–phosphate pathway (PPP), a metabolic route that contributes to the maintenance of neuronal redox status5–8. Astrocytes, in contrast, mainly obtain their cell energy needs from glycolysis, providing lactate as an oxidizable metabolic fuel to neurons9, which obtain energy mainly by the oxidative phosphorylation10.

A key factor that determines these metabolic features is 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3), a pro-glycolytic enzyme that is normally absent in neurons but abundant in astrocytes7. PFKFB3 activity produces fructose-2,6-bisphosphate (F2,6BP), a potent positive effector of the rate-limiting glycolytic enzyme, 6-phosphofructo-1-kinase (PFK1)10,11. The absence of PFKFB3 protein in neurons is due to its continuous degradation after ubiquitylation by the E3 ubiquitin ligase anaphase-promoting complex/cyclosome-Cdh1 (APC/C-Cdh1)7. In fact, APC/C-Cdh1 activity is higher in neurons than in astrocytes7. Notably, under certain neuropathological conditions, such as during excitotoxicity, the activity of APC/C-Cdh1 in neurons is inhibited12, which allows PFKFB3 protein stabilization in these cells13. Active neuronal PFKFB3 then stimulates glucose consumption through glycolysis, which results in a concomitant decreased PPP to cause redox stress and, eventually, apoptotic death13.

Stroke is the leading neurologic cause of morbidity and mortality in developed countries14. While the molecular mechanisms underlying this complex pathological condition are not yet completely understood, a large body of experimental data suggest that excitotoxicity, leading to mitochondrial dysfunction and increased reactive...
oxygen species (ROS) are contributing factors. Therefore, it appears reasonable that ameliorating the cascade of events triggered by excitotoxic stimuli might be a promising therapeutic strategy against stroke. Accordingly, we reasoned whether pharmacological inhibition of PFKFB3, by preventing the redox stress associated with glycolytic activation, would protect neurons from the apoptotic death upon excitotoxic insults. Here, we report that small molecule inhibitor of PFKFB3 is able to protect against the apoptotic death caused by excitotoxic stimuli and an oxygen-glucose deprivation (OGD)/reoxygenation model in mouse primary cortical neurons. Furthermore, we show that in vivo administration of this PFKFB3 inhibitor protects against motor discoordination, neurological deficiency and brain damage in a mouse model of brain ischemia/reperfusion.

**Results**

*In vitro* characterization of two PFKFB3 inhibitors. First, we evaluated the efficacy of two known PFKFB3 inhibitors at inhibiting the ability of A549 cells to produce F2,6BP, namely AZ67 (ref.18), and PFK158, an improved derivative of the widely used compound, 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one 1 (3PO) 19. As shown in Fig. 1a,b, both compounds (AZ67 and PFK158) were able to reduce the cellular levels of F2,6BP in a dose-dependent manner, with IC50 of 0.51 μM and 5.90 μM, respectively. Next, we investigated whether the reduction of cellular F2,6BP levels was a result of direct PFKFB3 inhibition. To do so, we used an enzymatic cell-free assay, which revealed that AZ67 inhibited the enzymatic activity of PFKFB3 with an IC50 of 0.018 μM (Fig. 1c), a value that is in accordance with previously published results18. However, surprisingly, PFK158 had no effect on PFKFB3 enzymatic activity at any of the concentrations tested (up to 100 μM) (Fig. 1d). Accordingly, although PFK158 is able to decrease F2,6BP (Fig. 1b) and glycolytic flux 20, our data show that these effects are not due to PFKFB3 enzymatic inhibition. Since in this study we are focused specifically on PFKFB3 given its particular protein stability feature and potential impact on neurodegeneration, we did not consider PFK158 for further analyses.

AZ67 protects neurons against proteasome inhibition and β-amyloid treatment. Since, in neurons, PFKFB3 is continuously degraded by the proteasome, we reasoned that the stabilization of PFKFB3 caused by proteasomal inhibition may trigger neuronal apoptosis. As shown in Supplementary Fig. S1a, AZ67 lacks toxicity in the range 0.01–100 nM for 24 h in mouse cortical primary neurons. Incubation of neurons with MG132, a widely used proteasomal inhibitor, significantly increased neuronal apoptosis (Fig. S1a), an effect that was dose-dependently counteracted by AZ67 (minimum effective dose, 1 nM; maximum effect at 10 nM), suggesting the involvement of PFKFB3 activity in MG132-mediated neuronal death. To investigate if AZ67 protects neurons from the toxicity caused by PFKFB3 stabilization upon a different kind of stimulus, we next used the amyloidogenic fragment 25–35 of the amyloid-β peptide (Aβ25–35), known to activate glutamate receptors21 and to inhibit Cdh1 (ref.22), i.e. conditions that stabilize PFKFB3 (ref.13). Incubation of neurons with Aβ25–35 increased

![Figure 1. In vitro characterization of two PFKFB3 inhibitors.](image-url)
Figure 2. AZ67 prevents glycolytic activation, redox stress and neuronal death upon excitotoxic stimuli in primary neurons. (a) Western immunoblotting showing that the treatment of neurons with glutamate (100 µM; 10 mins), followed by washout, stabilized PFKFB3 protein levels after 24 h of incubation. Incubation of neurons with AZ67 (10 nM) for 24 h, after glutamate was removed, did not alter PFKFB3 protein levels. (b) Incubation of neurons with AZ67 for 24 h revealed no effect on lactate release. Treatment of neurons with NMDA (100 µM; 10 mins) or glutamate (100 µM; 10 mins), followed by washout, increased lactate released after 24 h of incubation (compare NMDA or glutamate versus none values at 0 nM AZ67). Incubation of neurons with AZ67 for 24 h, after NMDA or glutamate was removed, dose-dependently prevented the increase in lactate release. (c) Incubation of neurons with AZ67 for 24 h revealed no effect on F2,6BP concentrations. Treatment of neurons with NMDA (100 µM; 10 mins) or glutamate (100 µM; 10 mins), followed by washout, increased F2,6BP after 24 h of incubation. Incubation of neurons with AZ67 (10 nM) for 24 h, after NMDA or glutamate was removed, prevented the increase in lactate release. (d) Incubation of neurons with AZ67 for 24 h revealed no significant effect on the NADPH/NADP ratio. Treatment of neurons with NMDA (100 µM; 10 mins) or glutamate (100 µM; 10 mins), followed by washout, decreased the NADPH/NADP ratio after 24 h of incubation. Incubation of neurons with AZ67 (10 nM) for 24 h, after NMDA or glutamate was removed, prevented the decreased NADPH/NADP ratio. (e) Incubation of neurons with AZ67 for 24 h revealed no effect on mitochondrial ROS. Treatment of neurons with NMDA (100 µM; 10 mins) or glutamate (100 µM; 10 mins), followed by washout, increased mitochondrial ROS after 24 h of incubation (compare NMDA or glutamate versus none values at 0 nM AZ67). Incubation of neurons with AZ67 for 24 h, after NMDA or glutamate was removed, dose-dependently prevented the increase in mitochondrial ROS. (f) Treatment of neurons with NMDA (100 µM; 10 mins) or glutamate (100 µM; 10 mins), followed by washout, triggered apoptotic death after 24 h of incubation (compare NMDA or glutamate versus none values at 0 nM AZ67). Incubation of neurons with AZ67 (10 nM) for 24 h, after NMDA or glutamate was removed, dose-dependently prevented apoptotic death. At concentrations of 100 nM to 10 µM, AZ67 showed progressive loss of protection. (g) Transfection of primary neurons with PfK1-M (4 µg of DNA plasmid) efficiently increased PfK1-M protein levels. (h) Treatment of neurons with glutamate (100 µM; 10 mins), followed by washout, triggered apoptotic death after 24 h of incubation. Incubation of neurons with AZ67 (10 nM) for 24 h, after glutamate was removed, prevented apoptotic death. However, AZ67-mediated protection of apoptotic death was abolished when neurons were previously transfected with the full-length cDNA coding for PfK1-M. Apoptosis was analysed only in the efficiently-transfected, GFP+ neurons. (i) Treatment of neurons with NMDA (100 µM; 10 mins), followed by washout, triggered apoptotic death after
neuronal apoptosis (Fig. S1a), and this effect was efficiently counteracted by AZ67 in a dose-dependent manner (minimum effective dose, 1 nM; maximum effect at 10 nM), thus suggesting that the excitotoxic effect of Aβ25-35 can, at least in part, be explained by PFKFB3 activation.

**AZ67 prevents glycolytic activation and redox stress upon excitotoxic stimuli in primary neurons.** To test the ability of AZ67 to protect against the damage caused by an excitotoxic stimulus, neurons were subjected to a short-term incubation with glutamate (100 µM for 10 minutes) followed by a 24 h incubation in glutamate-free culture medium, a widely-used excitotoxic protocol33. In good agreement with our previous observations33, this treatment triggered PFKFB3 protein stabilization (Figs 2a and S1b) and activated glycolysis, as judged by the increase in the release of the glycolytic end-product, lactate, to the culture medium after 24 h of incubation (Fig. 2b). Interestingly, the increased release of lactate was mimicked by treating neurons with the selective glutamate receptor agonist, N-methyl-D-aspartate (NMDA) (Fig. 2b), and was dose-dependently abrogated by incubation of neurons with AZ67 immediately after the excitotoxic stimuli during 24 h (Fig. 2b). The minimum concentration of AZ67 that showed to be fully effective at preventing the increase in lactate release was 1 nM, although at 10 nM, AZ67 was maximally effective in the glutamate-mediated stimulus (Fig. 2b). In good consistency with PFKFB3 protein stabilization13 (Fig. 2a), treatment of neurons with the excitotoxic stimuli increased the levels of the PFKFB3 product, F2,6BP, by almost ~3-fold (Fig. 2c), indicating increased PFKFB3 enzymatic activity. Notably, the increased F2,6BP levels were fully abolished by AZ67 at 10 nM (Fig. 2c) without affecting PFKFB3 protein stability (Fig. 2a). These data indicate that the pharmacological inhibition of PFKFB3 activity in neurons is sufficient to prevent excitotoxic stimulant-mediated activation of glycolysis. In contrast to neurons, astrocytes normally express high levels of PFKFB3 that are responsible for the high glycolytic phenotype of these glial cells47. Moreover, by activating PFKFB3, glycolysis further increases in astrocytes upon inhibition of mitochondrial cytochrome c oxidase with nitric oxide3,4. However, AZ67, at the low dose (10 nM) that is able to inhibit PFKFB3 activity in neurons (Fig. 2b), did not inhibit basal or nitric oxide-stimulated glycolysis in astrocytes (Fig. S1c). Since an increase in glycolysis leads to the impairment in the ability of neurons to regenerate NADPH through PPP activation7, we next assessed the redox state of this cofactor. As shown in Fig. 2d, stimulation of glutamate receptors triggered NADPH oxidation, a hallmark of PPP inhibition24,28, as judged by the decreased NADPH/NADP ratio, an effect that was abrogated by incubating neurons with AZ67 (10 nM). Given that PPP-mediated regeneration of oxidized NADPH is essential for preventing the redox stress in neurons7,13 that accompanies mitochondrial damage in several neurodegenerative diseases25,26, we next investigated mitochondrial reactive oxygen species (ROS). In good agreement with this notion, treatment of neurons with the excitotoxic stimuli promoted an increase in mitochondrial ROS (Fig. 2e), and this effect was abolished by AZ67 (10 nM) (Fig. 2e). Thus, inhibition of PFKFB3 activity upon an excitotoxic stimulus prevents the aberrant activation of glycolysis in neurons that leads to redox stress.

The neuroprotective effect of AZ67 against excitotoxicity is lost by genetically hampering glycolytic inhibition. Next, we aimed to further confirm whether AZ67, by preventing the activation of glycolysis in neurons, could account for the neuronal death associated with the excitotoxic stimuli. To do so, neurons were incubated with glutamate or NMDA, as above, and apoptosis assessed by annexin V+/7AAD− staining using flow cytometry. As shown in Fig. 2f, both types of excitotoxic stimuli significantly increased apoptotic neuronal death. Notably, this effect was dose-dependently prevented by AZ67, being 1 nM the minimum effective concentration and 10 nM the maximum dose showing protection (Fig. 2f). A progressive loss of protection was observed at AZ67 concentrations ≥100 nM (Fig. 2f). To address whether the neuronal protection exerted by AZ67 was a consequence of preventing the glycolytic activation, we assessed whether overexpression of the glycolytic enzyme, PFK1-muscle isoform, was able to rescue AZ67-mediated neuroprotection. We focused on the muscle PFK1 isoform (PFK1-M) given its low sensitivity to P2,6BP allosteric activation29, and, hence, its independence on PFKFB3 levels to fully activate glycolysis24. Accordingly, neurons were first transfected with the full-length cDNA encoding for PFK1-M (Figs 2g and S1d), and then subjected to the excitotoxic insults. As shown in Fig. 2h,i, PFK1-M over-expression was able to abrogate the neuroprotection caused by AZ67 (10 nM) against glutamate or NMDA-mediated neuronal apoptosis. These results confirm that the neuroprotection exerted by AZ67 is a consequence of its ability to prevent glycolytic activation.

AZ67 prevents the metabolic switch from PPP to glycolysis, redox and mitochondrial stress, and apoptosis in an in vitro model of ischemia/reperfusion in primary neurons. Next, we aimed to elucidate whether AZ67 is able to prevent the metabolic switch and loss of survival triggered by a different type of excitotoxic stimulus in neurons. Given that neuronal damage associated with the loss of oxygen and nutrient supply is known to take place through an excitotoxic pathway29,30, we prompted to investigate the potential beneficial effect of AZ67 in the in vitro model of oxygen and glucose deprivation (OGD)31. To do so, primary neurons were subjected to a 3 hours OGD incubation followed by a 4 hours reoxygenation (plus glucose) incubation period, a
Figure 3. AZ67 prevents the metabolic switch from PPP to glycolysis, redox and mitochondrial stress, and apoptosis in an in vitro model of ischemia/reperfusion in primary neurons. (a) Western immunoblotting showing that the treatment of neurons with OGD (3 h) followed by reoxygenation (plus glucose) (4 h), stabilized PFKFB3 protein levels. Incubation of neurons with AZ67 (10 nM) during the 4 h of reoxygenation did not alter PFKFB3 protein levels. (b) Incubation of neurons with AZ67 for 4 h revealed no effect on lactate release. Treatment of neurons with OGD (3 h) followed by reoxygenation (plus glucose) (4 h) increased lactate released. Incubation of neurons with AZ67 (10 nM) during the 4 h of reoxygenation prevented the increase in lactate release. (c) Incubation of neurons with AZ67 (10 nM) during the 4 h of reoxygenation prevented the increase in the glycolytic flux. Treatment of neurons with OGD (3 h) followed by reoxygenation (plus glucose) (4 h) increased the glycolytic flux. Incubation of neurons with AZ67 (10 nM) during the 4 h of reoxygenation prevented the increase in the glycolytic flux. (d) Incubation of neurons with AZ67 for 4 h revealed no effect on the pentose-phosphate pathway (PPP) flux, as assessed by the difference in the formation of $^{14}$CO$_2$ from [1-14C]-glucose, and from [6-14C]-glucose. However, treatment of neurons with OGD (3 h) followed by reoxygenation (plus glucose) (4 h) decreased the PPP flux. Incubation of neurons with AZ67 (10 nM) during the 4 h of reoxygenation prevented the decrease in the PPP flux. (e) Incubation of neurons with AZ67 (10 nM) during the 4 h of reoxygenation prevented the increase in H$_2$O$_2$ release. Treatment of neurons with OGD (3 h) followed by reoxygenation (plus glucose) (4 h) increased H$_2$O$_2$ release. Incubation of neurons with AZ67 (10 nM) during the 4 h of reoxygenation prevented the increase in H$_2$O$_2$ release. (f) Incubation of neurons with AZ67 (10 nM) during the 4 h of reoxygenation prevented the increase in mitochondrial ROS formation, as assessed by MitoSox fluorescence by flow cytometry. However, treatment of neurons with OGD (3 h) followed by reoxygenation (plus glucose) (4 h) increased mitochondrial ROS. Incubation of neurons with AZ67...
characterized in vitro model of ischemia. In good consonance with the excitotoxic models, OGD/reoxygenation triggered PFKFB3 protein stabilization (Figs 3a and S1e) and activated glycolysis, as judged by the increase in the release of lactate to the culture medium at the end of the reoxygenation period (Fig. 3b). Interestingly, the increased release of lactate was abrogated by incubation of neurons with AZ67 (10 nM) immediately after OGD, during the reoxygenation period (Fig. 3b). Notably, the increased release of lactate was fully abolished by AZ67 (10 nM) (Fig. 3b) without affecting PFKFB3 protein stability (Fig. 3a). To further confirm the activation of glycolysis in the OGD/reperfusion model, we determined the rate of [3-3H]glucose conversion into 3H2O, a bona fide measure of the glycolytic flux. Treatment of neurons with the OGD/reoxygenation protocol increased the glycolytic flux (Fig. 3c). Since increased glycolysis impairs glucose metabolism through PPP in neurons, we next assessed the rate of PPP flux using a radiometric approach based on determining the difference in the release of 14CO2 from neurons incubated with either [1-14C]pyruvate or [6-14C]glucose. As shown in Fig. 3d, OGD/reoxygenation triggered the inhibition of PPP flux. Interestingly, both the increase in glycolysis and the decrease in PPP were abrogated by incubating neurons with AZ67 (10 nM) (Fig. 3c,d). Since PPP is essential to maintain the antioxidant status of neurons, we investigated ROS. Treatment of neurons with the OGD/reoxygenation protocol increased H2O2 release from neurons (Fig. 3e) and mitochondrial ROS (Fig. 3f), effects that were significantly attenuated by AZ67 (10 nM) (Fig. 3e,f). These data indicate that OGD/reperfusion triggers a metabolic switch from PPP to glycolysis that is associated with redox stress, and that these effects are significantly prevented by AZ67. As expected, OGD/reoxygenation impaired mitochondrial intermediary metabolism as observed by the decreased oxidation of [1-14C]pyruvate (Fig. 3g), a measure of pyruvate dehydrogenase (PDH) activity. However, PDH activity was unaffected by AZ67, neither when added alone nor in the OGD/reoxygenation model (Fig. 3g). Altogether, these data strongly suggest that AZ67 primarily affects glucose transformation through glycolysis and, indirectly, PPP, without altering mitochondrial intermediary metabolism. Furthermore, OGD/reperfusion triggered a loss in the mitochondrial inner membrane potential (Δψm) (Fig. 3h), likely consequence of the associated redox stress-mediated damage of the mitochondrial respiratory chain. In good agreement with the redox stress rescue exerted by AZ67 (Fig. 3e,f), this compound significantly prevented the Δψm loss caused by OGD/reperfusion (Fig. 3h). To ascertain if AZ67 affected neuronal survival in the OGD/reperfusion model, we assessed caspase-3 activity as a measure of apoptosis. As shown in Fig. 3l, OGD/reperfusion increased neuronal apoptosis, an effect that was significantly rescued by AZ67 (10 nM).

In vivo AZ67 administration protects mice against the motor discoordination caused by a brain ischemia/reperfusion model. Finally, we aimed to investigate if AZ67 was able to exert neuroprotection in vivo. Since it is very well documented that brain injury in stroke occurs through an excitotoxic mechanism, we studied whether AZ67 protected against damage caused in a mouse model of stroke. To achieve this, we induced a transient ischemia (30 min) by occlusion of the middle carotid artery (MCAO model), followed by 24 h reperfusion as described by a well-established protocol. Twenty-four hours after the transient MCAO episode, mice were subjected to the rotarod test, which revealed a 40% performance of motor coordination in the MCAO group when compared with the sham-operated animals treated with vehicle (Fig. 4a). Following this analysis, animals were then subjected to neurological examination following the Bederson test. As shown in Fig. 4b, the results revealed severe neurological impairment (score >3) by MCAO. Immediately after the Bederson test, mice were euthanized to determine the percentage of infarcted volume in the brain, which resulted to be ≈43% in the MCAO group (0% in the vehicle, sham-operated animals) (Fig. 4c). AZ67 (60 mg/kg of body weight), or vehicle, were administered intravenously through the jugular vein immediately after the ischemic episode, at the start of the reperfusion. AZ67 administration in the sham-operated animals showed no signs of neurological deficit (NNS = 0 both for vehicle and AZ67; Fig. 4a), motor discoordination (Fig. 4b) or brain injury (Fig. 4c) after 24 h when compared with vehicle, sham-operated mice, indicating lack of AZ67 toxicity at the dose used. Although the use of only one dose of AZ67 might represent a study limitation, notably, AZ67 administration at the selected dose of 60 mg/kg of body weight significantly improved the neurological deficit (NNS = −2) (Fig. 4a), prevented the motor discoordination (~60% performance) (Fig. 4b) and decreased the infarcted brain volume to 27% (Fig. 4c).
Discussion

Here we show that pharmacological inhibition of PFKFB3 activity, by preventing glycolytic activation, protects neurons against excitotoxicity both in the NMDA and glutamate receptor activation models and in the oxygen-glucose deprivation/reperfusion model. Furthermore, PFKFB3 inhibition also showed brain damage protection in the MCAO ischemic/reperfusion model \textit{in vivo}. To our knowledge, this is the first time showing that inhibition of glycolysis, by the use of a small-molecule compound, shows a beneficial effect in a neurological disease model. In cancer cells, several PFKFB3 inhibitors of different chemical classes have been reported to inhibit glycolysis, on which these cells rely for proliferation and survival\textsuperscript{35–39}. Amongst these PFKFB3 inhibitors, 3PO and its derivative PFK158 have been reported to reduce the cellular levels of F2,6BP, inhibit glucose uptake and lactate production, thus facilitating apoptosis in cancer cells. However, on our hands, PFK158 is inactive as PFKFB3 inhibitor\textsuperscript{18} that, on our conditions, inhibited human recombinant PFKFB3 kinase activity with an IC\textsubscript{50} of 18 nM and decreased cellular F2,6BP production in A549 cells with an IC\textsubscript{50} of 510 nM. When compared with astrocytes and other tissues, neurons are, by far, the type of cell showing the smallest PFKFB3 abundance, which is virtually absent\textsuperscript{7}. In good agreement with this, we found that lower concentrations of AZ67 (in the 1–10 nM range) were sufficient to efficiently abrogate the enhancements in F2,6BP, glycolysis
and apoptosis in neurons. However, AZ67 was unable to decrease basal glycolysis nor to rescue the increased glycolytic activation in astrocytes. In vivo administration of the PFKFB3 inhibitor in the MCAO model could, in principle, enter all cells of the organism to broadly inhibit PFKFB3 activity. However, our data showing lack of effect of AZ67 in astrocytic glycolysis strongly supports the notion that neuronal glycolysis would be more sensitive than astrocytic to AZ67, which is in good agreement with the large difference in PFKFB3 abundance between neurons and astrocytes. This feature can be advantageous when determining the specific administration doses for future pre-clinical trials.

The rationale for targeting PFKFB3 and glycolysis as a therapeutic strategy for neurodegeneration relies on the physiological regulation of PFKFB3 protein stability in neurons. Thus, PFKFB3 is continuously degraded by the proteasome to keep glycolysis low in healthy neurons; however, PFKFB3 becomes stabilized upon proteasomal inhibition, leading to increased glycolysis and decreased PPP, which ultimately causes redox stress and neuronal death. In good agreement with this notion, our data show that PFKFB3 inhibition by AZ67 exerts neuroprotection after blocking the proteasome with MG132. Furthermore, AZ67 prevented the neuronal death triggered by the Alzheimer’s disease-related peptide Aβ25–35, known to promote the degradation of Chdh, i.e. the APC/C-cofactor necessary for PFKFB3 ubiquitylation and proteasomal degradation. In the neuronal models of excitotoxicity and OGD/reoxygenation, the increase in glycolysis was paralleled with NADPH oxidation and PPP inhibition, respectively. NADPH oxidation impairs glutathione regeneration thus causing redox stress, a feature that we have herein confirmed according to the increase mitochondrial ROS upon the excitotoxic and OGD/reoxygenation insults. Interestingly, AZ67 was able to rescue the enhancement in glycolysis, PPP inhibition, NADPH oxidation and redox stress, supporting the notion that restoring the equilibrium between glycolysis and PPP is a suitable and efficient neuroprotective strategy. Importantly, the neuroprotection exerted by AZ67 was abolished by over-expressing PFK1-M, an enzyme that activates glycolysis independently on F2,6BP levels. This result demonstrates that the neuroprotective effect of AZ67 is due to its ability to inhibit the increase in glycolysis.

Excitotoxicity is a hallmark of various neurodegenerative diseases including stroke. Moreover, there is both pre-clinical and clinical evidence that tissue plasminogen activator (tPA), the only approved drug treatment for acute ischemic stroke, despite its obvious benefits presents adverse effects in the brain, including excitotoxicity potentiation. Although neuroprotective strategies have been focused on NMDA receptor antagonists, unfortunately none of them have been successful, likely because functional NMDA receptors are essential for the normal brain physiology. Our data showing that targeting downstream the NMDA receptors activation -such as neuronal glycolysis-, rather than the NMDA receptors themselves, shows neuroprotection strongly suggest that targeting PFKFB3 would be a suitable alternative strategy for the prevention of the deleterious effects of NMDA receptor overstimulation in stroke and related excitotoxicity-associated neurological disorders, such as, amongst others, traumatic brain injury, Alzheimer’s or Parkinson’s diseases.

**Methods**

**Ethical use of animals.** All animal procedures we performed according to the European Union Directive 86/609/EEC and Recommendation 2007/526/EC, regarding the protection of animals used for experimental and other scientific purposes, enforced in Spanish legislation under the directive RD1201/2005. All protocols were approved by the Bioethics Committee of the University of Salamanca and by the Junta de Castilla y Leon (registration number 080).

**PFKFB3 Enzymatic assay.** Recombinant full length human PFKFB3 protein purified from S9 baculoviral system acquired from SignalChem (Cat. #P323-30G). ATP, fructose-6-phosphate (F6P) and other chemicals were from Sigma-Aldrich. ADP detection system (ADP-Glo) was purchased from Promega. Inhibitors were synthesized as described by Boyd et al. The kinase activity of the PFKFB3 protein was detected by measuring production of ADP from ATP in the presence of F6P. The reactions were assembled in 384 well plates in a total volume of 25 µL. Test compounds were serially diluted in dimethyl sulfoxide (DMSO). Reactions were setup by mixing test compounds with the enzyme and pre-incubating for 15 min. ATP and F6P were next added to initiate the reactions. The final assay composition included: 100 mM Tris-HCl pH 8.0, 4 mM MgCl₂, 5 mM KH₂PO₄, 5 mM DTT, 20 mM KF, 0.02% BSA, 1% DMSO (from the compounds), 15 mM enzyme, 20 µM ATP (Km = 16 µM) and 10 mM F6P (Km = 6 µM). We used a low concentration of PFKFB3 protein (15 nM) since concentrations higher than 50 nM showed to hydrolyze ATP in the absence of F6P. Thus, under the conditions used in our experiments, ADP formation was solely due to F6P phosphorylation by PFKFB3. The kinase reactions were allowed to proceed for 1 hour at room temperature. Aliquots of the reaction mixtures (5 µl) were transferred to fresh 384 well plates and mixed with 5 µl of the ADP-Glo reagent, followed by incubation for 30 min. The luminescent kinase detection reagent was added (10 µl) and, following additional incubation for 15 min, the plates were read with a luminescence plate reader (Analyzer HT). Positive (no enzyme; 100% inhibition) and negative (DMSO instead of AZ67 or PFK158; 0% inhibition) control samples were assembled in each assay plates and were used to calculate percent inhibition values of test compounds.

**Fructose-2,6-bisphosphate determinations.** For F2,6BP determinations, cells were lysed in 0.1 N NaOH and centrifuged (20,000 × g, 20 min). An aliquot of the homogenate was used for protein determination, and the remaining sample was heated at 80 °C (5 min), centrifuged (20,000 × g, 20 min) and the supernatant used for the determination of F2,6BP concentrations using the coupled enzymatic reaction and F2,6BP standards as described by Van Schaftingen.

**Cell culture.** Primary cultures of C57BL/6J mice cortical neurons were prepared from foetal animals of 14.5 days of gestation, seeded at 1.8·10⁵ cells/cm² in plastic plates coated with poly-D-lysine (10 mg/ml) and incubated in Neurobasal (Life Technologies) supplemented with 2 mM glutamine, 5 mM of glucose, 0.25 mM pyruvate and 2% B27 supplement (Life Technologies). Cells were incubated at 37 °C in a humidified 5% CO₂-containing
and further incubated in culture medium with the PFKFB3 inhibitors for 24 hours. For amyloid-β treatment, cells were incubated with 2 µM oligomerized Aβ25–35 (BioNova Cientifica S.L., Madrid, Spain) or the corresponding scramble non-aggregable peptide (Aβ35–42) (BioNova Cientifica S.L.), which was used as control. Neurons were incubated in culture medium containing oligomerized Aβ35–35 (10 µM) or the corresponding scramble non-aggregable peptide (Aβ35–42) in Neurobasal medium at 37 °C for 3 days to induce its oligomerization. We have shown that Aβ25–35 exerts neurotoxicity following identical mechanism to the full-length Aβ40–42 peptide. Neurons were incubated in culture medium containing oligomerized Aβ35–35 (10 µM) plus the corresponding scramble non-aggregable peptide (Aβ35–42) (BioNova Cientifica S.L.), which was used as control. Neurons were incubated in culture medium containing oligomerized Aβ35–35 (10 µM) plus the corresponding scramble non-aggregable peptide (Aβ35–42) (BioNova Cientifica S.L.), which was used as control.

Oxygen and glucose deprivation (OGD)/reoxygenation protocol. After 8 days in culture, neurons were subjected to oxygen and glucose deprivation (OGD) by incubating cells at 37 °C in an incubator equipped with an air lock and continuously gassed with 95% N2/5% CO2 for 3 hours. The incubation medium (Neurobasal medium without glucose) was previously gassed with 95% N2/5% CO2 for 5 min. In parallel, neurons were incubated in Neurobasal complete medium (normoxia condition) at 37 °C in a humidified atmosphere of 95% air/5% CO2. After OGD, neurons were further incubated for 4 hours with (or not) AZ67 10 nM to inhibit the proteasome, neurons were incubated with MG132 (10 µM) for 2 hours. To inhibit cytochrome c oxidase activity, astrocytes at 14 days in vitro were incubated with the nitric oxide donor, DETA-NONOate (0.5 mM) for 4 hours.

Western blotting. Neurons were lysed in RIPA buffer (2% sodium dodecylsulfate, 2 mM EDTA, 2 mM EGTA and 50 mM Tris pH 7.5), supplemented with protease and phosphatase inhibitor cocktail (100 µM phenylmethylsulfonyl fluoride, 50 µg/ml antipain, 50 µg/ml pepstatin, 50 µg/ml leupeptin, 50 µg/ml bestatin, 1 mM o-phenan-diamine, 50 mM NaF, and 50 µg/ml soybean trypsin inhibitor) and boiled for 5 min. Extracts were centrifuged at 13,000 × g for 5 min at 4 °C, and aliquots of lysates (50 µg protein, unless otherwise stated) were subjected to sodium dodecyl sulfate-polyacrylamide (SDS-PAGE) electrophoresis on a 8, 10 or 12% acrylamide gel (MiniProtean, Bio-Rad) including PageRuler Plus Prestained Protein Ladder (Thermo). The resolved proteins were transferred electrophoretically to nitrocellulose membranes (Hybond-ECL, Amersham Bioscience Europe GmbH, Barcelona, Spain). Membranes were blocked with 5% (w/v) low-fat milk in 20 mM Tris, 500 mM NaCl, and 0.1% (w/v) Tween 20, pH 7.5, for 1 h. After blocking, membranes were immunoblotted with primary antibodies at dilutions ranging from 1:500 to 1:40,000 overnight at 4 °C. After incubation with the secondary antibodies (all at 1:10,000 dilution), membranes were immediately incubated with the enhanced chemiluminescence kit WesternBright ECL (Advansta, Menlo Park, California, USA) for 2 min or SuperSignal West Fermo Maximum Sensitivity Substrate (Thermo Scientific, Offenbach, Germany) for 5 min, before exposure to Fuji Medical X-Ray film (Fujifilm), and the autoradiograms scanned. Biologically independent replicates were always performed (Supplementary Fig. S5), and a representative western blot is shown.

Primary antibodies for western blotting. Immunoblotting was performed using mouse monoclonal anti-PFKFB3 (1:500) (H0005209-M08, Novus Biologicals), mouse monoclonal anti-glyceraldehyde dehydrogenase (GAPDH; 1:40,000) (AM4300, Ambion) and antiserum against muscle PFK1 isoform (PFK1-M) (accession number, NM_000289.1) using Lipofectamine LTX-PLUS Reagent (Life Technologies) according with manufacturer’s protocol. Transfections were performed 24 hours before cells collection. Control cells were transfected with the empty vector.

Secondary antibodies for western blotting. Immunoblotting was performed using mouse monoclonal anti-PFKFB3 (1:500) (H0005209-M08, Novus Biologicals), mouse monoclonal anti-glyceraldehyde dehydrogenase (GAPDH; 1:40,000) (AM4300, Ambion) and antiserum against muscle PFK1 isoform (PFK1-M; 1:100).
H$_2$O$_2$ determination. For H$_2$O$_2$ assessments, AmplexRed (Life Technologies, New York, USA) was used. Cells grown on 96 wells plates were washed with PBS and incubated in KRPG buffer (NaCl 145 mM; NaHPO$_4$ 5.7 mM; KCl 4.86 mM; CaCl$_2$ 0.54 mM; MgSO$_4$ 1.22 mM; glucose 5.5 mM: pH 7.35) in the presence of 9.45 μCi D-[3-3H]glucose for 90 min, as previously described. Incubations were then terminated by the addition of 0.2 ml 20% perchloric acid, and the cells were further incubated for 96 h with a microcentrifuge tube containing H$_2$O$_2$, suspended above the cells to allow 3H$_2$O equilibration. The 3H$_2$O was then measured by liquid scintillation counting (Tri-Carb 4810 TR, PerkinElmer). Under these experimental conditions, 28% of the produced 3H$_2$O was recovered and used for the calculations as previously established.

Flow cytometric analysis of apoptotic cell death. APC-conjugated annexin-V and 7-amino-actinomycin D (7-AAD) (Becton Dickinson Biosciences, BDB, San Jose, CA, USA) were used to determine quantitatively the percentage of apoptotic neurons by flow cytometry. Cells were stained with annexin V-APC and 7-AAD, following the manufacturer’s instructions, and were analysed on a FACScalibur flow cytometer (15 mW argon ion laser tuned at 488 nm; CellQuest software, Becton Dickinson Biosciences) using the CellQuest software (BD Biosciences). Both GFP$^+$ and GFP$^-$ cells were analyzed separately, and the annexin V-APC-stained cells that were 7-AAD-negative were considered to be apoptotic (see, also, Supplementary Fig. S3 for the flow cytometry workflow for apoptosis).

Active caspase-3 determination. A fluorimetric caspase 3 assay kit (Sigma-Aldrich) was used following the manufacturer’s protocol. This assay is based on the hydrolysis of the peptide substrate Ac-DEVD-AMC (acetyl-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin) by caspase-3, which results in the release of fluorescent 7-amino-4-methylcoumarin (AMC). In brief, cells were lysed with 50 mM HEPES, 5 mM CHAPS, 5 mM DTT, pH 7.4 for 20 min on ice, and the assay buffer containing the Ac-DEVD-AMC substrate (20 mM HEPES, 2 mM EDTA, 0.1% CHAPS, 5 mM DTT, 16 μM Ac-DEVD-AMC) was transferred to a 96-wells plate and the fluorescence recorded for 30 mins at 5 mins intervals at 37 °C ($\lambda_{\text{em}} = 360$ nm, $\lambda_{\text{exc}} = 440$ nm). CSP-3 activity was determined as AMC release rate extrapolating the slopes to those obtained from an AMC standard curve. Results are expressed as fold change, arbitrarily assigning the value of 1 to control cells.

NADPH/NADP$^+$ ratio determination. This was performed using the colorimetric NADPH/NADP assay kit (Abcam). Cells were re-suspended in 500 μl of NADPH/NADP extraction buffer, vortexed and centrifuged at 14,000 rpm for 3 minutes to remove insoluble material. The supernatant was used for NADPH plus NADP measurement. NADPH was determined in 200 μl of the supernatant, after heated at 60 °C for 30 minutes to decompose NADP. Actual NADP and NADPH concentrations were calculated by extrapolating values to a NADPH standard curve (0–100 pmol/well).

Determination of the pentose-phosphate pathway (PPP) flux. PPP flux was measured in 8 cm$^2$ flasks of adherent cells at 60–70% confluence containing a central microcentrifuge tube with 0.8 ml benzethonium hydroxide (Sigma) for 14CO$_2$ equilibration. Incubations were carried out in KRPG containing 5.5 mM D-glucose at 37 °C in the air-thermostatized chamber of an orbital shaker (Forma Benchtop Orbital Shaker, Model 420, Thermo Fischer). To ensure adequate oxygen supply for oxidative metabolism throughout the incubation period, flasks were filled with oxygen before being sealed. To measure the carbon flux from glucose through the PPP, cells were incubated in KRPG (5 mM D-glucose) buffer supplemented with 0.5 μCi D-[1-14C]glucose or D-[6-14C]glucose for 90 min, as previously described. Incubations were then terminated by the addition of 0.2 ml 20% perchloric acid (Merck Millipore) for 30 min before the benzethonium hydroxide (containing 14CO$_2$) was removed, and the radioactivity was measured with a liquid scintillation analyzer (Tri-Carb 4810 TR, PerkinElmer). PPP flux was calculated as the difference between 14CO$_2$ production from [1-14C]glucose (which decarboxylates through the 6-phosphogluconate dehydrogenase–catalyzed reaction) and that of [6-14C]glucose (which decarboxylates through the TCA cycle).

Determination of the glycolytic flux. Glycolytic flux was measured in 8 cm$^2$ flasks of adherent cells at 60–70% confluence containing a central microcentrifuge tube with 1 ml H$_2$O for 3H$_2$O equilibration. Incubations were carried out in KRPG containing 5.5 mM D-glucose at 37 °C in the air-thermostatized chamber of an orbital shaker (Forma Benchtop Orbital Shaker, Model 420, Thermo Fischer). To ensure adequate oxygen supply for oxidative metabolism throughout the incubation period, flasks were filled with oxygen before being sealed. Glycolytic flux was measured by assaying the rate of H$_2$O production from [3-3H]glucose by incubating cells with 5 μCi D-[3-3H]glucose in KRPG buffer per flask for 120 h, as previously described. Incubations were then terminated with 0.2 ml 20% perchloric acid, and the cells were further incubated for 96 h with a microcentrifuge tube containing H$_2$O$_2$, suspended above the cells to allow H$_2$O$_2$ equilibration. The H$_2$O$_2$ was then measured by liquid scintillation counting (Tri-Carb 4810 TR, PerkinElmer). Under these experimental conditions, 28% of the produced H$_2$O$_2$ was recovered and used for the calculations as previously established.

Lactate determination. Lactate released to the culture medium was determined as an estimation of glycolysis. To do so, the increments in absorbance of the culture medium samples were measured at 340 nm in a mixture containing 1 mM NAD$^+$ and 22.5 units/ml of lactate dehydrogenase in 0.25 M glycine/0.5 M hydrazine/1 mM EDTA at pH 9.5.

Pyruvate dehydrogenase (PDH) activity. PDH was measured in 8 cm$^2$ flasks of adherent cells at 60–70% confluence containing a central microcentrifuge tube with 0.8 ml benzethonium hydroxide (Sigma) for 14CO$_2$ equilibration. Incubations were carried out in KRPG containing 5.5 mM D-glucose and 1 mM pyruvate at 37 °C in the air-thermostatized chamber of an orbital shaker (Forma Benchtop Orbital Shaker, Model 420, Thermo
Fischer). To ensure adequate oxygen supply for oxidative metabolism throughout the incubation period, flasks were filled with oxygen before being sealed. To measure the carbon flux from pyruvate through the tricarboxylic acid cycle (TCA), cells were incubated in KRPG (5.5 mM D-glucose and 1 mM pyruvate), buffer supplemented with 0.5 μCi D-[1-14C]pyruvate for 90 min, as previously described. Incubations were then terminated by the addition of 0.2 ml 20% perchloric acid (Merck Millipore) for 30 min before the benzenthonium hydroxide (containing 14CO2) was removed, and the radioactivity was measured with a liquid scintillation analyzer (Tri-Carb 4810 TR, PerkinElmer). PDH activity was determined as the rate of [1-14C]pyruvate decarboxylation to 14CO2 through the TCA cycle.

Mitochondrial membrane potential (Δψm). Δψm was assessed using Mito Probe DiIC(5) Assay Kit for flow cytometry (Molecular Probes Europe BV, Leiden, Netherlands) on a FACScalibur flow cytometer (15 mW argon ion laser tuned at 488 nm; CellQuest software, Becton Dickinson Biosciences). Δψm values were expressed as percentages, using carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (CCCP; 10 μM) for 15 min to define the 0% Δψm values (see, also, Supplementary Fig. S4 for the flow cytometry workflow for mitochondrial membrane potential).

Transient middle cerebral artery occlusion (MCAO). Surgical endovascular insertion of a silicon-coated monofilament (602012PK10; Doccol Corporation, Sharon, MA, USA) was performed to induce transient middle cerebral artery occlusion (MCAO) for 30 minutes of ischemia, followed by filament removal to allow reperfusion . Briefly, 10-weeks-old C57BL/6J mice were anesthetized with sevoflurane (4% for induction, 3% for maintenance) in a mixture of O2/N2O (30/70%). After surgical exposure of the right carotid artery tree, the filament was inserted through the external carotid artery and advanced through the internal carotid artery until it reached the middle cerebral artery. The regional cerebral blood flow was monitored during surgery with a laser Doppler probe (Moor Instruments, Devon, UK). After 30 minutes of ischemia, the filament was removed to allow reperfusion. AZ67 (60 mg/kg of body weight) or vehicle were administered in a bolus (200 μl) via the jugular vein immediately after reperfusion. Body temperature was maintained at 37 ± 0.5 °C using a heating pad connected to a rectal probe (BAT-12 thermometer; Physitemp Instruments Inc., Clifton, NJ, USA). Mice were then sutured and returned to the cages. Sham-operated mice underwent the same surgical procedure without middle cerebral artery occlusion.

Rotarod analysis. An accelerating rotarod test was used to determine motor coordination. Animals were trained during the immediate three previous days of the MCAO surgery. The first day, mice stayed on the rotarod at a constant speed of 4 rpm, and the remaining 2nd and 3rd day they stayed at an accelerating speed (4 to 40 rpm in 5 mins). For the test, which was performed 24 hours after the MCAO surgery, mice were subjected to three consecutive trials at the accelerating speed for 5 mins (at 15 mins intervals). The latency to fall was determined and expressed in seconds.

Neurological severity score (NSS). For the NSS test, mice were examined to assess the neurological status using a 0–5 grading scale as described. Mice treated with the vehicle (DMSO) were scored 0, while dead mice were scored 5. The rest of the animals were examined and assigned a score for each of the following five items, following the test description, namely (i) spontaneous activity, (ii) spontaneous rightward rotation, (iii) rightward deficit after grabbing the animal by the tail and (v) moving it closer to the platform.

Infarct volume. Immediately after the rota-rotd test, mice were euthanized by cervical dislocation after CO2 overdose, and the brain extracted and sliced in 2-mm coronal sections with a brain matrix on ice, which were used to determine the infarct volume after incubation of the slices in 2% (wt/vol) 2,3,5-triphenyltetrazolium chloride in phosphate-buffered saline (136 mM NaCl, 27 mM KCl, 7.8 mM Na2HPO4, 1.7 mM KH2PO4, pH 7.4) for 20 minutes at room temperature. Pictures of the brain sections were taken, and the images processed using the NIH-image processing package ImageJ. Infarct volumes were determined by multiplying the selected infarcted area by the width of the slices. In order to correct the infarct volume by the edema, the ratio lesion volume of the ipsilateral (affected) versus that of the contralateral (unaffected) hemispheres was calculated. The percentage of infarct volume was calculated using the following formula: (infarcted volume corrected by edema × 100)/Infarcted hemisphere volume.

Statistical analysis. Results from cultured cells were obtained from 3 independent culture preparations using 4–6 technical replicates per sample. Data were expressed as mean ± standard error of the mean (SEM) values, using as “n” the number of independent culture preparations. Statistical analysis of the results was performed by one-way or two-way analysis of variance (ANOVA), followed by the least significant difference multiple range test. In all cases, p < 0.05 was considered significant. Statistics were performed using Microsoft Excel or the IBM SPSS Statistics software.

Data Availability All data generated or analysed during this study are included in this published article.

References
1. Bolaños, J. P., Almeida, A. & Moncada, S. Glycolysis: a bioenergetic or a survival pathway? Trends Biochem Sci 35, 145–149 (2010).
2. Bolaños, J. P., Peuchen, S., Heales, S. J. R., Land, J. M. & Clark, J. B. Nitric oxide-mediated inhibition of the mitochondrial respiratory chain in cultured astrocytes. J. Neurochem. 63, 910–916 (1994).
28. Almeida, A., Bolaños, J. P. & Moncada, S. E3 ubiquitin ligase APC/C-Cdh1 accounts for the Warburg effect by linking glycolysis to mitochondrial ATP synthesis by nitric oxide synthase activation triggered by biochemical, immunochimical and kinetic studies. *Biochem J* 299, 333–341 (1985).

29. Almeida, A., Bolaños, J. P. & Moncada, S. 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3). *Adv. Nutr. Food Sci.*, 107:119–130 (2010).

30. Mallios, J. A. A polymorphism in the EAAT2 promoter is associated with higher glutamate concentrations and higher frequency of progressing stroke. *J. Neurol. Sci.* 216, 13–18 (2004).

31. Rodriguez, et al. Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer. *Mol Cancer Ther* 12, 1029–1039 (2013).

32. Pyrkov, V. et al. Targeting 6-phosphofructo-2-kinase (PFKFB3) and modulates cyclin B1 stability in excitotoxicity. *Embo J* 27, 2736–2745 (2008).

33. Rodriguez-Rodriguez, P., Fernandez, E. & Bolaños, J. P. Excitotoxic stimulus stabilizes PFKFB3 causing pentose-phosphate pathway in intact primary cortical neurons. *Neurosci. Lett.* 232, 9–27 (1997).

34. Bederson, J. B. & Ross, B. D. Assessment of the role of the glutathione and pentose phosphate pathways in the protection of primary cerebrocortical cultures from oxidative stress. *J. Neurochem.* 66, 2329–2337 (1996).

35. Clem, B. F. & Boxer, P. A. & Ross, B. D. Single-Nucleotide Polymorphism 309T > G in the MDM2 Promoter Determines Functional Outcome After Stroke. *Stroke: a journal of cerebral circulation* 49, 2437–2444 (2018).

36. Vicente-Gutierrez, C. et al. Astrocytic mitochondrial ROS modulate brain metabolism and mouse behavior. *Nat Metab* 1, 201–211 (2019).

37. Engell, O., Kolodziej, S., D'Intrigo, U. & Prinz, V. M. Modeling Stroke in Mice - Middle Cerebral Artery Occlusion with the Filament Model. *Journal of Visualized Experiments* 47, e2423 (2011).

38. Bederson, J. B. et al. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. *Stroke* 17, 472–476 (1986).

39. Clem, B. et al. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. *Mol Cancer Ther* 7, 110–120 (2008).

40. Wang, Y. F. et al. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. *Nat Med* 4, 228–231 (1998).

41. Iglesias-Rev, R. et al. Worse Outcome in Stroke Patients Treated with rt-PA Without Early Reperfusion: Associated Factors. *Transl Stroke Res* 9, 347–355 (2018).

42. Macrez, R., Bezir, I., Le Mauff, B., Ali, C. & Vivien, D. Functional occurrence of the interaction of tissue plasminogen activator with the NRI Subunit of N-methyl-D-aspartate receptors during stroke. *Stroke* 41, 2950–2955 (2010).

43. Van Schaftingen, F., J. D'Urso, R. Bartrons, R. & Hers, H. G. A kinetic study of pyrophosphorylase: fructose-6-phosphate phosphotransferase from potato tubers. Application to a microassay of fructose 2,6-bisphosphatase. *Eur J Biochem* 129, 191–195 (1982).
44. Almeida, A., Bolaños, J. P. & Moreno, S. Cdh1/Hct1-APC is essential for the survival of postmitotic neurons. *J Neurosci.* 25, 8115–8121 (2005).

45. Requejo-Aguilar, R. *et al.* PINK1 deficiency sustains cell proliferation by reprogramming glucose metabolism through HIF1. *Nat Commun* 5, 4514 (2014).

**Acknowledgements**

J.P.B. is funded by the MINECO (SAF2016-78114-R), CIBERFES (CB16/10/00282), H2020 European Commission (BatCure Grant 666918), Ayudas Fundación BBVA a Equipos de Investigación Científica en Biomedicina 2017 and Fundación Ramón Areces. A.A. is funded by H2020 European Commission (PANA grant 686009), Instituto de Salud Carlos III (PI15/00473; RD16/0019/0018) and Fundación Ramón Areces. J.P.B. and A.A. are in part funded by FEDER. This work was part of the “Escalera de Excelencia” program of the Junta de Castilla y León (CLU-2017-03) co-funded by the P.O. FEDER of Castilla y León 14–20. We acknowledge the technical assistance of Monica Resch, Monica Carabias-Carrasco, Lucia Martin and Estefania Prieto-Garcia from the University of Salamanca. O.B., T.E., D.S. and P.O.F. were funded by Gero Discovery L.L.C. and acknowledge extensive technical assistance from and insightful discussions with Tim Pyrkov, Christina Khodorova, and Geny Getmantsev from Gero team. We appreciate S. Romanov and Nanosyn team for help with the synthesis and biological evaluation of PFKFB3 inhibitors.

**Author Contributions**

O.B., T.E., D.S., S.R., K.Z. and P.O.F. were involved in planning the study and in vitro characterization the PFKFB3 inhibitors, participating in the manuscript preparation. A.O.-A., R.L., D.J.-B. and A.A. performed research. J.P.B. participated in the study design, co-supervision and manuscript writing. All the authors reviewed the final version of the paper.

**Additional Information**

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-48196-z.

**Competing Interests:** P.O.F. is a shareholder of Gero Discovery L.L.C. O.B., D.S. and P.O.F. are employees of Gero Discovery L.L.C. The company develops PFKFB3 inhibitors and holds I.P. covering small molecules inhibitors of PFKFB3 and their therapeutic applications.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019